Zobrazeno 1 - 10
of 17
pro vyhledávání: '"John R Foringer"'
Autor:
Donald A. Molony, Hei Kit Chan, Henry E Wang, John R Foringer, Julianna West, David J. Robinson
Publikováno v:
JAMA Network Open. 3:e1921447
Autor:
Kevin W. Finkel, John R Foringer
Publikováno v:
Nature Clinical Practice Nephrology. 3:669-678
Kidney disease is very common in patients with cancer. Nephrologists are vital members of the multidisciplinary care team for these patients. Given the high prevalence of comorbidities in patients treated for active malignancy, it is not surprising t
Autor:
Regina R. Verani, Ruchdi K Barakat, Navneet Singh, Rajiv Lal, Kevin W. Finkel, John R Foringer
Publikováno v:
Annals of Pharmacotherapy. 41:707-710
Objective: To report a case of interstitial nephritis associated with the administration of bevacizumab. Case Summary: A 26-year-old man diagnosed with metastatic rectal leiomyosarcoma was treated with intravenous bevacizumab 5 mg/kg and received a t
Publikováno v:
Annals of Pharmacotherapy. 40:2254-2259
Objective: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity. Case Summary: A 41-year-ol
Autor:
Ioannis Chatzinikolaou, Issam I Raad, John R Foringer, Tam Ho, Kevin W. Finkel, Hend Hanna, Maha Boktour
Publikováno v:
The American Journal of Medicine. 115:352-357
Purpose To determine the efficacy of minocycline-rifampin–coated hemodialysis catheters in reducing catheter-related infections in patients requiring hemodialysis for acute renal failure. Methods Between May 2000 and March 2002, 66 patients were ra
Publikováno v:
American Journal of Kidney Diseases. 55:A35-A37
Autor:
Regina R. Verani, John R Foringer, Joshua Samuels, Vincent M Tjia, Jayarama S Guntupalli, Kevin W. Finkel
Publikováno v:
Annals of Pharmacotherapy. 39:2136-2138
OBJECTIVE To report a case of acute renal failure associated with the administration of imatinib mesylate. CASE SUMMARY A 64-year-old man diagnosed with prostate cancer was enrolled in a Phase I trial of imatinib mesylate plus taxotere on a protocol
Autor:
Andrew Advani, Michael Allon, Amanda Hyre Anderson, Gerald B. Appel, Suheir Assady, Anthony Atala, Colin Baigent, Sevcan A. Bakkaloglu, Gina-Marie Barletta, Gavin J. Becker, Rinaldo Bellomo, Jeffrey S. Berns, Vivek Bhalla, Jürg Biber, Daniel G. Bichet, René J.M. Bindels, Melissa B. Bleicher, Jon D. Blumenfeld, Alain Bonnardeaux, Joseph V. Bonventre, William D. Boswell, Donald W. Bowden, Barry M. Brenner, Matthew D. Breyer, Richard M. Breyer, Dennis Brown, Carlo Brugnara, Timothy E. Bunchman, David A. Bushinsky, Stéphan Busque, Juan Jesús Carrero, Daniel Cattran, James C. Chan, Anil Chandraker, Ingrid J. Chang, Devasmita Choudhury, Fredric L. Coe, John F. Collins, H. Terence Cook, Ricardo Correa-Rotter, Shawn E. Cowper, Paolo Cravedi, Alfonso M. Cueto-Manzano, Vivette D. D’Agati, Mogomat Razeen Davids, Scott E. Delacroix, Bradley M. Denker, Thomas A. Depner, Thomas D. DuBose, Kai-Uwe Eckardt, Mohamed T. Eldehni, David H. Ellison, Michael Emmett, Ronald J. Falk, Harold I. Feldman, Robert A. Fenton, Andrew Z. Fenves, Kevin W. Finkel, Paola Fioretto, Damian G. Fogarty, John R. Foringer, Denis Fouque, Barry I. Freedman, Jørgen Frøkiaer, John W. Funder, David S. Game, Richard E. Gilbert, Jared J. Grantham, Mitchell L. Halperin, Matthew Hand, Donna S. Hanes, David C.H. Harris, Raymond C. Harris, Richard Haynes, Joost G.J. Hoenderop, Ewout J. Hoorn, Thomas H. Hostetter, Chi-yuan Hsu, Shih Hua-Lin, Hassan N. Ibrahim, Ajay K. Israni, Jossein Jadvar, J. Charles Jennette, Eric Jonasch, Kamel S. Kamel, S. Ananth Karumanchi, Bertram L. Kasiske, John A. Kellum, Carolyn J. Kelly, Ramesh Khanna, David K. Klassen, Christine J. Ko, Harbir Singh Kohli, Curtis K. Kost, L. Spencer Krane, Jordan Kreidberg, Tae-Hwan Kwon, Amit Lahoti, Martin J. Landray, John H. Laragh, Harold E. Layton, Moshe Levi, Bengt Lindholm, Frank Liu, Valerie A. Luyckx, David A. Maddox, Yoshiro Maezawa, Arthur J. Matas, Michael Mauer, Ivan D. Maya, Sharon E. Maynard, Alicia A. McDonough, Christopher W. McIntyre, Timothy W. Meyer, William E. Mitch, Orson W. Moe, Sharon M. Moe, Bruce A. Molitoris, Alvin H. Moss, David B. Mount, Karen A. Munger, Patrick H. Nachman, Saraladevi Naicker, Søren Nielsen, Eric G. Neilson, Lindsay E. Nicolle, Daniel B. Ornt, Manuel Palacín, Paul M. Palevsky, Suzanne L. Palmer, Hans-Henrik Parving, Jaakko Patrakka, David Pearce, Roberto Pecoits-Filho, Carmen A. Peralta, Norberto Perico, Neil R. Powe, Kearkiat Praditpornsilpa, Jeppe Prætorius, Susan E. Quaggin, L. Darryl Quarles, Jai Radhakrishnan, Rawi Ramadan, Piero Reggenenti, Heather N. Reich, Andrea Remuzzi, Giuseppe Remuzzi, Stephen S. Rich, Miguel C. Riella, Eberhard Ritz, Claudio Ronco, Norman D. Rosenblum, Peter Rossing, Dvora Rubinger, Robert K. Rude, Ernesto Sabath, Venkata Sabbisetti, Vinay Sakhuja, Alan D. Salama, Jeff M. Sands, Fernando Santos, Mohamed H. Sayegh, John D. Scandling, Franz Schaefer, Jon I. Scheinman, John C. Schwartz, Asif A. Sharfuddin, Susan Shaw, Visith Sitprija, Karl L. Skorecki, Itzchak N. Slotki, James P. Smith, Miroslaw J. Smogorzewski, Stuart M. Sprague, Peter Stenvinkel, John B. Stokes, Maarten W. Taal, Manjula Kurella Tamura, Jane C. Tan, Stephen C. Textor, Ravi Thadhani, Scott C. Thomson, Vincente E. Torres, Karl Tryggvason, Meryem Tuncel, Kriang Tungsanga, Joseph G. Verbalis, Jill W. Verlander, Shoyab Wadee, I. David Weiner, Matthew R. Weir, Steven D. Weisbord, David C. Wheeler, Christopher S. Wilcox, Christopher G. Wood, Stephen H. Wright, Jane Y. Yeun, Alan S.L. Yu, Kambiz Zandi-Nejad, Mark L. Zeidel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de5115257fa97cfd01b685f539f4c4e6
https://doi.org/10.1016/b978-1-4160-6193-9.10164-2
https://doi.org/10.1016/b978-1-4160-6193-9.10164-2
Publikováno v:
Cancer treatment reviews. 36(2)
Tumor lysis syndrome (TLS) is a potentially life-threatening metabolic disorder that occurs when tumor cells undergo rapid decomposition spontaneously or in response to cytoreductive therapy. Delayed recognition of the metabolic imbalances caused by